Two RCTs reported cannabis use outcomes following pharmacological interventions: one in people with major depression, alcohol dependence and cannabis abuse diagnoses (n = 22; fluoxetine vs placebo) and one in people with schizophrenia and cannabis and / or cocaine use disorders (n = 28; olanzapine
vs risperidone).